Vunakizumab for inflammatory skin diseases
Part of Skin clinical trials.
This trial tests a new medicine called vunakizumab for various inflammatory skin diseases like eczema or psoriasis. If you have such a conditionwit, this study may help see how well the treatment works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with an inflammatory skin condition like eczema, psoriasis, or a similar issue.
- You are about to start or are currently using vunakizumab for your skin condition.
- You agree to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at inflammation in people with vitiligo, psoriasis, atopic dermatitis, or alopecia areata. It aims to understand how these conditions compare, which may lead to better treatments.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study tests a new biologic medicine called vunakizumab for people with moderate to severe plaque psoriasis whose current biologic treatment isn't working well enough. The goal is to see if switching to vunakizumab can improve skin symptoms and is safe.
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.